ST 1535: A preferential A2A adenosine receptor antagonist

International Journal of Neuropsychopharmacology

Volumn 9, Issue 5, 2006, Pages 575-584

  Stasi, Maria Antonietta ^a   Borsini, Franco ^a   Varani, Katia ^b   Vincenzi, Fabrizio ^b   Di Cesare, Maria Assunta ^a   Minetti, Patrizia ^a   Ghirardi, Orlando ^a   Carminati, Paolo ^a  

^a Sigma Tau SpA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

A2A adenosine receptors; cAMP; Ccatalepsy; Motor activity; Mouse models of Parkinson; ST 1535

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 BUTYL 9 METHYL 8 (2H 1,2,3 TRIAZOL 2 YL) 9H PURIN 6 YLAMINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; CYCLIC AMP; HALOPERIDOL; LEVODOPA; PURINE DERIVATIVE; ST 1535; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HYPERACTIVITY; IC 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENINE; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; BEHAVIOR, ANIMAL; CATALEPSY; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; MOTOR ACTIVITY; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A2A; TIME FACTORS; TRANSFECTION; TRIAZOLES; TRITIUM; XANTHINES;

EID: 33750200622     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705006188     Document Type: Article

References (37)

1. 2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. Pharmacology and Toxicology 62, 121-130.
2. 2A receptor antagonist treatment of Parkinson's disease. Neurology 61, 293-296.
3. Bradford MM (1976). A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye-binding. Analytical Biochemistry 72, 248.
4. 2A receptors plus L-dopa after nigrostriatal lesion results in GAD67 mRNA changes different from L-dopa alone in the rat globus pallidus and substantia reticolata. Experimental Neurology 184, 679-687.
5. 50) of an enzymatic reaction. Biochemical Pharmacology 22, 3099-3108.
6. 2A antagonist KF 17837 reverses the locomotor suppression and tremolous induced by haloperidol in rats: possible relevance to parkinsonism. Behavioral Brain Research 148, 47-54.
7. Costall B, Naylor RJ, Nohria V (1979). Hyperactivity response to apomorphine and amphetamine in the mouse: the importance of the nucleus accumbens and caudate-putamen. Journal of Pharmacy and Pharmacology 41, 259-261.
8. 2A receptor ligand. European Neuropsychopharmacology 13 (Suppl. 4), S397.
9. 2A receptor knockout mice. British Journal of Pharmacology 134, 688-677.
10. 2A receptor. European Journal of Pharmacology 401, 63-77.
11. Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K (1997). Adenosine-dopamine receptor interactions as an integrative mechanism in the basal ganglia. Trends in Neurosciences 20, 482-487.
12. 2A receptor antagonist 8-(3-chlorostyryl)caffeine on L-dopa biotransformation in rat striatum. Brain Research 998, 208-217.
13. 2A receptor antagonist in MPTP-treated monkeys. Neurology 52, 1673-1677.
14. Haley TJ, McCormick WG (1957). Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. British Journal of Pharmacology 12, 12-15.
15. 2A receptor antagonist istradefylline in advanced PD. Neurology 61, 297-303.
16. 2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology 11, S32-S38.
17. 2A antagonist: a novel antiparkinson agent that does not provoke dyskinesia in parkinsonian monkeys. Annals of Neurology 43, 507-513.
18. 2A receptor antagonist with anticataleptic activity. European Journal of Pharmacology 256, 263-268.
19. 2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 28, 1281-1291.
20. Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ (1998). Comparative pharmacology of human adenosine subtypes - characterization of stably tansfected receptor in CHO cells. Naunyn Schmiedeberg's Archives of Pharmacology 357, 1-9.
21. Nieri P, Martinotti E, Caldrone V, Breschi MC (2001). Adenosine-mediated hypotension in in vivo guinea-pig: receptors involved and role of NO. British Journal of Pharmacology 134, 745-752.
22. 2-receptor antagonists induce catalepsy via different efferent striatal pathways. Neuroscience Letters 85, 333-338
23. (Erratum in Neuroscience Letters 89, 259).
24. 2 receptors modulate extracellular dopamine levels in rat striatum. Neuroscience Letters 212, 53-56.
25. 1 receptor antagonist BIIP20 counteracts scopolamine-induced behavioral deficits in the passive avoidance task in the rat. European Journal of Pharmacology 328, 19-22.
26. 2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats. Neuroscience Letters 251, 201-204.
27. 2 receptors modulates the social recognition memory in reserpine-trated rats. Behavioural Parmacology 16, 209-218.
28. Rex SC, Kramar EA, Colgin LL, Lin B, Gall M, Lynch G (2005). Long-term potentiation is impaired in middle-aged rats: regional specificity and reversal by adenosine receptor antagonists. Journal of Neuroscience 25, 5956-5966.
29. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 147, 90-95.
30. 2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Experimental Neurology 189, 182-188.
31. 2A receptor ligand. European Neuropsychopharmacology 13 (Suppl. 4), S401-S402.
32. Svenningsson P, le Moine C, Fisone G, Fredholm BB (1999). Distribution, biochemistry and function of striatal adenosine A2a receptors. Progress in Neurobiology 59, 355-396.
33. 2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NFGI-A and NFGI-B in caudate-putamen and nucleus accumbens. Neurosciences 79, 753-764.
34. 2 interactions in models of Parkinson disease. Parkinson Related Disorders 10, 273-282.
35. 3H]-CGS 21680 binding. British Journal of Pharmacology 117, 1693-1701.
36. 3 adenosine receptors. Molecular Pharmacology 57, 968-975.
37. 1 adenosine antagonists enhance the anticataleptic action of trihexyphenidyl in rats. Neuroscience Letters 346, 1-4.